Literature DB >> 18684170

The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance.

Beth P Bell1, M Michele Manos, Atif Zaman, Norah Terrault, Ann Thomas, Victor J Navarro, Kathy B Dhotre, Rosemary C Murphy, Grace R Van Ness, Nicole Stabach, Marie E Robert, William A Bower, Stephanie R Bialek, Andre N Sofair.   

Abstract

OBJECTIVES: Chronic liver disease (CLD) is an important cause of morbidity and mortality, but the epidemiology is not well described. We conducted prospective population-based surveillance to estimate newly diagnosed CLD incidence, characterize etiology distribution, and determine disease stage.
METHODS: We identified cases of CLD newly diagnosed during 1999-2001 among adult county residents seen in any gastroenterology practice in New Haven County, Connecticut; Multnomah County, Oregon; and Northern California Kaiser Permanente Medical Care Program (KPMCP, Oakland, California [total population 1.48 million]). We defined CLD as abnormal liver tests of at least 6 months' duration or pathologic, clinical, or radiologic evidence of CLD. Consenting patients were interviewed, a blood specimen obtained, and the medical record reviewed.
RESULTS: We identified 2,353 patients with newly diagnosed CLD (63.9 cases/100,000 population), including 1,225 hepatitis C patients (33.2 cases/100,000). Men aged 45-54 yr had the highest hepatitis C incidence rate (111.3/100,000). Among 1,040 enrolled patients, the median age was 48 yr (range 19-86 yr). Hepatitis C, either alone (442 [42%]) or in combination with alcohol-related liver disease (ALD) (228 [22%]), accounted for two-thirds of the cases. Other etiologies included nonalcoholic fatty liver disease (NAFLD, 95 [9%]), ALD (82 [8%]), and hepatitis B (36 [3%]). Other identified etiologies each accounted for <3% of the cases. A total of 184 patients (18%) presented with cirrhosis, including 44% of patients with ALD.
CONCLUSIONS: Extrapolating from this population-based surveillance network to the adult U.S. population, approximately 150,000 patients with CLD were diagnosed in gastroenterology practices each year during 1999-2001. Most patients had hepatitis C; heavy alcohol consumption among these patients was common. Almost 20% of patients, an estimated 30,000 per year, had cirrhosis at presentation. These results provide population-level baseline data to evaluate trends in identification of patients with CLD in gastroenterology practices.

Entities:  

Mesh:

Year:  2008        PMID: 18684170     DOI: 10.1111/j.1572-0241.2008.02071.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  48 in total

1.  Shear-wave elastography for the estimation of liver fibrosis in chronic liver disease: determining accuracy and ideal site for measurement.

Authors:  Anthony E Samir; Manish Dhyani; Abhinav Vij; Atul K Bhan; Elkan F Halpern; Jorge Méndez-Navarro; Kathleen E Corey; Raymond T Chung
Journal:  Radiology       Date:  2014-11-13       Impact factor: 11.105

2.  Hepatic lipogranulomas in patients with chronic liver disease: association with hepatitis C and fatty liver disease.

Authors:  Hongfa Zhu; Henry C Bodenheimer; David J Clain; Albert D Min; Neil D Theise
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

Review 3.  Estimating the true prevalence of hepatitis C in rhode island.

Authors:  Elizabeth N Kinnard; Lynn E Taylor; Omar Galárraga; Brandon D L Marshall
Journal:  R I Med J (2013)       Date:  2014-07-01

4.  Underestimation of liver-related mortality in the United States.

Authors:  Sumeet K Asrani; Joseph J Larson; Barbara Yawn; Terry M Therneau; W Ray Kim
Journal:  Gastroenterology       Date:  2013-04-09       Impact factor: 22.682

5.  Complementary and alternative medicine use in chronic liver disease patients.

Authors:  Leah M Ferrucci; Beth P Bell; Kathy B Dhotre; M Michele Manos; Norah A Terrault; Atif Zaman; Rosemary C Murphy; Grace R Vanness; Ann R Thomas; Stephanie R Bialek; Mayur M Desai; Andre N Sofair
Journal:  J Clin Gastroenterol       Date:  2010-02       Impact factor: 3.062

Review 6.  The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis.

Authors:  Johannes Wiegand; Thomas Berg
Journal:  Dtsch Arztebl Int       Date:  2013-02-08       Impact factor: 5.594

7.  Physical, social, and psychological consequences of treatment for hepatitis C : a community-based evaluation of patient-reported outcomes.

Authors:  M Michele Manos; Chanda K Ho; Rosemary C Murphy; Valentina A Shvachko
Journal:  Patient       Date:  2013       Impact factor: 3.883

8.  A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients.

Authors:  Jorge Méndez-Navarro; Ruby A Chirino; Kathleen E Corey; Emmanuel C Gorospe; Hui Zheng; Segundo Morán; Jesus A Juarez; Raymond T Chung; Margarita Dehesa-Violante
Journal:  Dig Dis Sci       Date:  2009-12-04       Impact factor: 3.199

9.  T2 relaxation time is related to liver fibrosis severity.

Authors:  Alexander R Guimaraes; Luiz Siqueira; Ritika Uppal; Jamu Alford; Bryan C Fuchs; Suguru Yamada; Kenneth Tanabe; Raymond T Chung; Gregory Lauwers; Michael L Chew; Giles W Boland; Duhyant V Sahani; Mark Vangel; Peter F Hahn; Peter Caravan
Journal:  Quant Imaging Med Surg       Date:  2016-04

10.  Etiology of liver cirrhosis in Japan: a nationwide survey.

Authors:  Kojiro Michitaka; Shuhei Nishiguchi; Yutaka Aoyagi; Yoichi Hiasa; Yoshio Tokumoto; Morikazu Onji
Journal:  J Gastroenterol       Date:  2009-09-30       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.